当前位置: 首页 >> 检索结果
523. Letter by Hu et al Regarding Article, "Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation".524. Response by Patel and Giugliano to Letter Regarding Article, "Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation".525. Response by Abdel-Qadir et al to Letter Regarding Article, "Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study".
作者: Husam Abdel-Qadir.;Kavi Grewal.;Xuesong Wang.;Peter C Austin.;Cynthia A Jackevicius.;Inbar Nardi Agmon.;Dennis T Ko.;Douglas S Lee.;Paaladinesh Thavendiranathan.;Michael Fradley.;Paul Dorian.
来源: Circulation. 2025年152卷22期e421-e422页 526. Chordin-Like 1 mRNA Therapy for Acute Myocardial Infarction.
作者: Mateusz Tomczyk.;Izabela Kraszewska.;Gang Li.;Matthew John Hayes.;Luca Venditti.;Josef Huntington.;Chun Kit Wong.;Angelica Cadoni.;Francesca Bortolotti.;Antonio Mura.;Manendra Pachauri.;Gianfranco Sinagra.;Mauro Giacca.
来源: Circulation. 2025年152卷22期1586-1589页 530. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
作者: Sotirios Tsimikas.;Michael Szarek.;Christa M Cobbaert.;Fred Romijn.;J Wouter Jukema.;Deepak L Bhatt.;Vera A Bittner.;Rafael Diaz.;Sergio Fazio.;Genevieve Garon.;Chong Yuan.;Xiao-Min Gong.;Shaun G Goodman.;Harvey D White.;Joseph L Witztum.;P Gabriel Steg.;Gregory G Schwartz.; .
来源: Circulation. 2025年152卷24期1666-1678页
Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome in recent the era is not known.
531. Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation.
作者: Ashley Park.;Temesgen E Andargie.;Xin Tian.;Michael Keller.;Isabella Cavagna.;Neelam Redekar.;Tom Hill.;Hyesik Kong.;Woojin Park.;Xinyue Zhao.;Prasanthy Balasubramanian.;Daniel Tang.;Andrew Karaba.;Moon Jang.;Michael A Solomon.;Hannah Valantine.;Palak Shah.;Sean Agbor-Enoh.
来源: Circ Heart Fail. 2026年19卷1期e013302页
Adverse events after durable left ventricular assist devices (LVADs) pose a challenge to survival. However, there are limited risk stratification approaches. Plasma cell-free DNA (cfDNA) offers potential as a biomarker for assessing end-organ injury and risk stratification.
535. Proteomic Signatures Involved in Cardiac Recovery After Mechanical Unloading.
作者: Yukako Shintani-Domoto.;Koji L Ode.;Seitaro Nomura.;Yoshiki Nagashima.;Osamu Kinoshita.;Manami Katoh.;Takanobu Yamada.;Eisuke Amiya.;Kanna Fujita.;Hiroyuki Abe.;Tetsuo Ushiku.;Issei Komuro.;Minoru Ono.;Hiroki R Ueda.;Masashi Fukayama.
来源: Circulation. 2025年152卷21期1518-1521页 536. Global Proteoform Alterations Across Multiple Cellular Compartments Underlie Obstructive Hypertrophic Cardiomyopathy.
作者: Zhan Gao.;Kalina J Rossler.;Holden T Rogers.;Zachery R Gregorich.;Timothy J Aballo.;Emily A Chapman.;Scott J Price.;Joshua Hermsen.;Willem J de Lange.;Yanlong Zhu.;Boqian Zhang.;Jiaqi Chen.;J Carter Ralphe.;Timothy J Kamp.;Ying Ge.
来源: Circ Heart Fail. 2025年18卷12期e012899页
Hypertrophic cardiomyopathy (HCM) has traditionally been regarded as a disease of the sarcomere; however, it is in the midst of a paradigm shift with growing recognition of contributions beyond the sarcomere to the heterogeneity of HCM phenotypes. Innovative approaches are essential to uncover novel determinants and mechanisms underlying this heterogeneity. Top-down proteomics has emerged as a powerful method for analysis of proteoforms-the myriad protein products arising from genetic variants, posttranslational modifications, and splicing isoforms from a single gene-offering a more precise lens to understand the disease heterogeneity in HCM. Yet, how proteoforms are altered on a global scale in HCM has not been investigated.
537. Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade.
作者: Julian S Wanner.;Maren Krafft.;Teemu Niiranen.;Dominic S Zimmerman.; FinnGen.;Patrick T Ellinor.;Girish Nadkarni.;Sean J Jurgens.;Joel Rämö.;Henrike O Heyne.
来源: Circulation. 2025年152卷24期1679-1690页
Atrial fibrillation and other cardiac arrhythmias pose a major public health burden, but prevention remains difficult. We investigated a genetic variant that we found to act like a natural lifelong cardiac sodium channel blockade.
540. Machine Learning Model for Atherosclerosis Evaluation and Cardiovascular Risk Prediction Based on Coronary CT Angiography-Analysis From the CREATION Registry.
作者: Ying Song.;Na Xu.;Jianan Zheng.;Sida Jia.;Cheng Cui.;Yin Zhang.;Lijian Gao.;Zhan Gao.;Jue Chen.;Lei Song.;Jinqing Yuan.;Bin Lu.;Zhi-Hui Hou.
来源: Circ Cardiovasc Imaging. 2025年18卷12期e018443页
Current atherosclerotic cardiovascular disease risk prediction tools based on traditional risk factors and the coronary artery calcium score have limitations.
|